# Evolution Agent Output

**Cycle ID:** 3  
**Revision type:** Merge, refine, and conditional extension of the top two axes; down‑scoped revision of the third axis, as instructed.

Based on the Proximity Check, Reflection, Ranking, and Meta‑review feedback, all near‑duplicate hypotheses within each cluster were merged. The resulting three merged hypotheses were refined to:

- Strengthen the causal direction while preserving direction‑level resolution,
- Explicitly separate the core hypothesis from provisional candidate examples,
- Foreground missing product measurements as prerequisites for forward progress,
- Incorporate the experimental validation criteria in a way that directly addresses key uncertainties,
- Remove or clearly downgrade any unsupported claims (e‑g., that spermidine/spermine or hypoxanthine production is confirmed; that specific immune subsets are the effectors; that *Pnp* is MK‑specific).

The strong consensus is to advance **H3** (AMD1‑eIF5A → direct vascular‑wall/matrix remodelling) and **H1** (AMD1‑polyamine → immune‑mediated remodelling) as the highest‑priority axes. **H2** (Pnp‑purine catabolism → immune remodelling) is retained only in a heavily revised, conditional form that makes its evidentiary gaps and lower MK specificity explicit; it should be considered a secondary hypothesis pending metabolite and functional data.

---

## Revised Hypothesis 1

**Original Hypothesis IDs:** generation_metabolic H1, generation_1 H1, generation_2 H1  
**Revised Hypothesis ID:** EVO‑H1  

**Revision type:** Merge + refine + clarify gaps  

**PI feedback addressed:** Refined immune‑mediated axis 1 – AMD1‑polyamine → immune‑mediated vascular remodelling. Emphasis on paracrine ligand‑receptor mechanisms (brief). Must anchor on new evidence tables, avoid over‑resolution.

**Revised hypothesis title:** MK‑AMD1‑polyamine → paracrine immune‑mediated pulmonary vascular remodelling

**Revised core directional hypothesis:**  
Hypoxia‑induced methionine accumulation and AMD1 up‑regulation in lung megakaryocytes drive polyamine (spermidine/spermine) synthesis. Secreted polyamines, or polyamine‑dependent immune‑modulatory factors produced via eIF5A hypusination, act on perivascular T‑cells and macrophages to create a pro‑remodelling immune milieu, thereby promoting medial thickening, muscularisation, and vascular stiffness.

**Revised direction‑level reasoning summary:**  
- **Data anchor:** MK‑sorted methionine is strongly elevated (log2FC +3.26, PH‑CD41 vs. Control‑CD41; `priority_metabolite_crosscheck.csv`). *Amd1* is MK‑enriched (enrichment log2 1.35) and significantly PH‑up in MKs (log2FC +1.77, p = 6.6 × 10⁻⁶; `priority_gene_seurat_expression.csv`).  
- **Biological interpretation:** Methionine accumulation in the absence of a concurrent SAM rise suggests diversion into the polyamine pathway. AMD1 (rate‑limiting for decarboxylated SAM) is the key enzymatic link; its strong induction predicts enhanced spermidine/spermine synthesis, although spermidine/spermine were not measured.  
- **MK‑linked pathway logic:** Methionine → SAM → dcSAM (via AMD1) → spermidine/spermine. Polyamines can be exported or packaged; they may act as paracrine signals on immune cells, or fuel eIF5A hypusination to selectively translate immunomodulatory proteins. The exact mode of transfer remains unresolved.  
- **Candidate downstream axis:** Immune‑mediated – polyamines alter perivascular T‑helper cell differentiation (e.g., Th17‑like tone) and/or macrophage polarization, eliciting cytokines that activate medial smooth muscle cells. All specific immune cell subsets and cytokines are provisional.  
- **Remodelling logic:** Immune‑driven growth factors and inflammatory mediators stimulate smooth‑muscle hypertrophy/hyperplasia, medial thickening, and muscularisation, contributing to vascular stiffness.  
- **Key uncertainty:** Spermidine/spermine levels and eIF5A hypusination have not been measured in MKs. It is unknown whether polyamines are directly secreted or act via polyamine‑dependent translational programmes. The perivascular immune target cell and the receptor(s) involved remain unspecified. MK spatial proximity to immune cells is unproven.  

**Revised directional chain:**
1. Hypoxia → methionine accumulation and AMD1 up‑regulation in lung MKs.  
2. AMD1 drives polyamine synthesis; spermidine/spermine pools are inferred to expand.  
3. MK‑derived polyamines (or polyamine‑dependent secreted factors) modulate perivascular T‑cell and macrophage programmes.  
4. Broad downstream axis: immune‑mediated (e.g., Th17‑like tone, macrophage activation).  
5. Immune‑derived mediators stimulate medial smooth‑muscle hypertrophy and extracellular matrix deposition → muscularisation, medial thickening, stiffness.  

**Candidate downstream axes:**  
- Plausible axes: (i) Polyamines taken up by CD4⁺ T‑cells promote Th17‑like differentiation; (ii) Polyamines polarise macrophages toward a pro‑fibrotic phenotype; (iii) Polyamine‑dependent eIF5A hypusination enhances MK secretion of cytokines/chemokines that recruit/activate immune cells.  
- Working model (provisional): MK‑released spermidine acts on perivascular T‑cells to favour a Th17‑biased environment, with IL‑17 driving VSMC activation.  
- Specific examples kept provisional: Th17‑like tone, IL‑17, macrophage M1/M2 shift, NLRP3, A2B receptor, TAARs, GPRC6A.  
- What remains unresolved: Identity of the dominant MK‑derived mediator (free polyamine vs. polyamine‑dependent cytokine); which immune sensor/receptor mediates the effect; whether MK‑specific polyamine blockade alters immune composition in vivo.  

**Evidence retained:**  
- User‑provided data: MK methionine log2FC +3.26; *Amd1* MK enrichment and PH‑up (as above).  
- Literature: AMD1‑polyamine‑eIF5A axis in cancer translation control (indirect).  
- Biological rationale: Polyamines are known immunomodulators; MKs reside in the perivascular niche.  

**Evidence added:** None; no new data.  

**Unsupported claims removed or downgraded:**  
- Removed any implication that spermidine/spermine elevation is confirmed; now explicitly labelled as inferred and unmeasured.  
- Downgraded “Th17‑like tone” to a candidate working model, not a committed pathway.  
- Removed any suggestion that eIF5A hypusination is directly linked to immune cytokine translation without evidence.  

**Improved experimental validation:**  
- **Perturbation:** Bone‑marrow‑specific (Pf4‑Cre) *Amd1* knockout or pharmacological AMD1 inhibitor (SAM486A) under hypoxia.  
- **Model:** Mouse hypoxia‑induced PH (10% O₂, 3–4 weeks).  
- **Readout:** RVSP, medial thickness, muscularisation, perivascular immune cell profiling (flow cytometry, IHC), MK spermidine/spermine levels (LC‑MS), lung polyamine content.  
- **Control:** Wild‑type littermates; vehicle‑treated mice.  
- **Expected result:** Loss of MK *Amd1* reduces lung polyamines, alters perivascular T‑cell/macrophage composition (e.g., fewer IL‑17⁺ cells), and attenuates vascular remodelling.  
- **Falsifying result:** MK‑specific AMD1 deletion does not reduce lung polyamine levels, or polyamine reduction fails to change immune composition and remodelling.  

**Remaining weaknesses:** Spermidine/spermine measurement is missing; mode of polyamine export from MKs unknown; eIF5A hypusination not assayed; spatial relationship between MKs and immune cells not established.  

**Pre‑requisite validation requirements:**  
- Demonstrate elevated spermidine/spermine in PH‑MKs vs. control MKs by LC‑MS.  
- Confirm that MK‑conditioned medium from hypoxic MKs contains elevated polyamines and/or immune‑modulatory activity.  

**Recommendation:** Ready for PI review as a top‑2 axis; requires metabolite validation before functional in vivo experiments.

---

## Revised Hypothesis 2

**Original Hypothesis IDs:** generation_metabolic H3, generation_1 H3, generation_2 H3  
**Revised Hypothesis ID:** EVO‑H3  

**Revision type:** Merge + refine + consolidate matrix remodelling axis  

**PI feedback addressed:** Conditional matricellular/secretome axis – AMD1‑polyamine‑eIF5A metabolic control of thrombospondin‑1, PDGF‑B, TGF‑β1 secretion → direct vascular‑wall/matrix remodelling. Must use confirmed MK‑enriched/PH‑up genes and anchor on metabolic evidence.

**Revised hypothesis title:** MK‑AMD1‑polyamine‑eIF5A axis controls a matricellular secretome (THBS1, PDGF‑B, TGF‑β1) that directly remodels the pulmonary vascular wall

**Revised core directional hypothesis:**  
Hypoxia‑induced AMD1 up‑regulation and methionine accumulation in lung MKs drive spermidine synthesis, which serves as the substrate for eIF5A hypusination. Hypusinated eIF5A selectively enhances translation of *Thbs1*, *Pdgfb*, and *Tgfb1* mRNAs, leading to coordinated secretion of thrombospondin‑1, PDGF‑B, and TGF‑β1. These paracrine ligands act on endothelial cells, vascular smooth‑muscle cells, and perivascular fibroblasts to induce endothelial dysfunction, smooth‑muscle proliferation, and matrix deposition, directly causing medial thickening, muscularisation, and stiffness.

**Revised direction‑level reasoning summary:**  
- **Data anchor:** *Amd1* is MK‑enriched (log2 1.35) and PH‑up (log2FC +1.77, p=6.6e‑06); MK methionine is up (+3.26). In the Seurat table, *Thbs1*, *Pdgfb*, and *Tgfb1* are all MK‑expressed, MK‑enriched, and PH‑up in MKs (e.g., Thbs1 enrichment log2 2.34, PH‑up log2FC 1.43, p=1.1e‑10; Pdgfb enrichment 2.02, PH‑up log2FC 0.98, p=0.001; Tgfb1 enrichment 0.82, PH‑up log2FC 0.74, p=0.0001).  
- **Biological interpretation:** The coincident induction of a polyamine‑synthesis enzyme and a suite of pro‑remodelling matricellular proteins suggests a metabolic‑translational control node. AMD1‑dependent spermidine is the exclusive substrate for eIF5A hypusination, a modification that facilitates translation of specific mRNAs with complex structural features or polyproline motifs – features present in *Thbs1*, *Pdgfb*, and *Tgfb1*. Thus, AMD1 activity may act as a permissive switch for the coordinated production of these proteins.  
- **MK‑linked pathway logic:** Methionine → AMD1 → spermidine → eIF5A hypusination → translational enhancement of *Thbs1*, *Pdgfb*, *Tgfb1*. The link between AMD1 and eIF5A is biochemically established; the specificity for these three transcripts is inferred and remains to be validated.  
- **Candidate downstream axis:** Direct vascular‑wall/matrix remodelling. Secreted THBS1 activates latent TGF‑β1 and engages CD36/CD47 on endothelial cells (anti‑angiogenic, pro‑apoptotic); PDGF‑B is a potent smooth‑muscle mitogen via PDGFRβ; TGF‑β1 promotes fibroblast‑to‑myofibroblast transition and collagen synthesis. Together, these effects recapitulate the key features of hypoxia‑induced vascular remodelling.  
- **Remodelling logic:** Coordinated release of these factors increases medial smooth‑muscle hyperplasia, perivascular fibrosis, and endothelial dysfunction, resulting in medial thickening, muscularisation, and vascular stiffness.  
- **Key uncertainty:** Spermidine, eIF5A hypusination, and the translation‑ control of these specific mRNAs have not been directly measured in MKs. The assumption that eIF5A hypusination governs *Thbs1*, *Pdgfb*, and *Tgfb1* translation is based on motif predictions and analogous studies in cancer cells. Secretion of these proteins from hypoxic MKs and their relative contribution to remodelling in vivo are untested.  

**Revised directional chain:**
1. Hypoxia → methionine accumulation and AMD1 up‑regulation in MKs.  
2. AMD1 drives spermidine synthesis (inferred).  
3. Spermidine serves as substrate for eIF5A hypusination (inferred).  
4. Hypusinated eIF5A enhances translation of *Thbs1*, *Pdgfb*, *Tgfb1* mRNAs (inferred).  
5. MKs secrete THBS1, PDGF‑B, TGF‑β1 into the perivascular space.  
6. Paracrine actions on endothelial cells (EC dysfunction), VSMCs (proliferation), and fibroblasts (fibrosis) → medial thickening, muscularisation, stiffness.  

**Candidate downstream axes:**  
- Plausible axes: (i) PDGF‑B‑driven SMC hyperplasia; (ii) THBS1‑mediated TGF‑β1 activation and perivascular fibrosis; (iii) TGF‑β1‑dependent myofibroblast transition and collagen deposition.  
- Working model (provisional): Combined secretion of THBS1, PDGF‑B, and TGF‑β1 acts cooperatively; THBS1 activates latent TGF‑β1, while PDGF‑B directly drives VSMC proliferation.  
- Specific examples kept provisional: CD36, PDGFRβ, TGFBR, ALK5, Smad2/3, perivascular fibrosis.  
- What remains unresolved: Whether eIF5A hypusination directly controls these transcripts in MKs; the relative contribution of each factor; whether MKs are the dominant source of these proteins in the perivascular niche.  

**Evidence retained:**  
- User‑provided data: *Amd1* and methionine changes (as above); *Thbs1*, *Pdgfb*, *Tgfb1* expression and PH‑up in MKs (Seurat table).  
- Literature: AMD1‑polyamine‑eIF5A axis in cancer (indirect); PDGF‑B, TGF‑β1, THBS1 in PH (indirect).  

**Evidence added:** None.  

**Unsupported claims removed or downgraded:**  
- Explicitly noted that spermidine, eIF5A hypusination, and translational control are inferred, not demonstrated.  
- Removed any suggestion that these three genes are proven eIF5A targets; now labelled as candidate target mRNAs.  
- Downgraded the working model from “coordinated release” to a plausible but unproven cooperative mechanism.  

**Improved experimental validation:**  
- **Perturbation:** Bone‑marrow‑specific *Amd1* KO, or pharmacological inhibition of eIF5A hypusination (GC7, deoxyhypusine synthase inhibitor).  
- **Model:** Mouse hypoxia‑PH, or co‑culture of hypoxic MKs with PASMCs/endothelial cells.  
- **Readout:** MK secretion of THBS1, PDGF‑B, TGF‑β1 (ELISA); eIF5A hypusination status (Western); polysome profiling of *Thbs1*, *Pdgfb*, *Tgfb1* mRNAs; medial thickness, collagen content, α‑SMA, RVSP.  
- **Expected result:** AMD1 loss or hypusination blockade reduces secretion of these proteins and attenuates vascular muscularisation and fibrosis.  
- **Falsifying result:** Intervention fails to alter secretion of these proteins, or remodelling is unchanged despite reduced secretion, indicating that other cell sources or factors dominate.  

**Remaining weaknesses:** Spermidine and hypusinated eIF5A not measured; translational control unproven; relative contribution of MK‑derived proteins vs. other lung cells unknown.  

**Pre‑requisite validation requirements:**  
- Measure spermidine in sorted PH‑MKs and demonstrate elevation.  
- Show that hypoxic MKs have increased hypusinated eIF5A.  
- Validate by polysome profiling or ribosome‑footprinting that *Thbs1*, *Pdgfb*, *Tgfb1* mRNAs are enriched in hypusination‑dependent translation fractions.  

**Recommendation:** Top priority for PI review; strong candidate with clear testable predictions, but requires metabolite and translation‑control validation before in vivo genetic experiments.

---

## Revised Hypothesis 3 (Conditional, down‑scoped)

**Original Hypothesis IDs:** generation_metabolic H2, generation_1 H2, generation_2 H2  
**Revised Hypothesis ID:** EVO‑H2‑Conditional  

**Revision type:** Merge + major revision + explicit deprioritisation  

**PI feedback addressed:** Refined immune‑mediated axis 2 – Pnp‑purine catabolism → immune‑mediated vascular remodelling. Must incorporate new inosine data (decreased, log2FC –0.34) and strong *Pnp* up‑regulation, but avoid adenosine‑accumulation model. Pnp is not MK‑enriched, so MK‑specific contribution is uncertain.

**Revised hypothesis title (conditional):** MK *Pnp*‑purine catabolism may contribute to perivascular immune activation via hypoxanthine/xanthine/ROS, but MK specificity remains unproven  

**Revised core directional hypothesis:**  
Hypoxia up‑regulates *Pnp* (and *Nt5c2*) in lung MKs, channelling purine nucleosides toward degradation; the modest decrease in MK inosine (log2FC –0.34) is consistent with accelerated catabolism. If MK‑derived hypoxanthine/xanthine and subsequent xanthine oxidase‑dependent ROS generation occur at functional levels, they could activate perivascular macrophages (e.g., NLRP3 inflammasome) and contribute to immune‑mediated medial remodelling. However, because *Pnp* is not MK‑enriched and its products have not been measured, the MK‑specific contribution remains speculative and this hypothesis is conditional on future metabolite data.

**Revised direction‑level reasoning summary:**  
- **Data anchor:** *Pnp* is PH‑up in MKs (log2FC +1.74, p=3.8e‑06) and *Nt5c2* is also up (log2FC +2.88). MK inosine shows a small decrease (–0.34), and whole‑lung inosine and adenosine are unchanged.  
- **Biological interpretation:** Elevated PNP activity likely converts inosine to hypoxanthine, explaining the inosine drop. Subsequent xanthine oxidase would generate xanthine/uric acid and superoxide. These purine catabolites are known immune danger signals.  
- **MK‑linked pathway logic:** Pnp is a direct enzyme for inosine; however, *Pnp* MK enrichment is negative (log2 –1.22), meaning expression is lower in MKs than in other lung cells. The PH‑up regulation within MKs could still increase local catabolism; however, other cell types likely contribute more total PNP activity.  
- **Candidate downstream axis:** Immune‑mediated – hypoxanthine/xanthine/uric acid and ROS could activate perivascular macrophages (NLRP3, IL‑1β) or directly damage vascular cells.  
- **Remodelling logic:** ROS and inflammasome‑derived cytokines promote inflammation and VSMC proliferation, leading to medial thickening.  
- **Key uncertainty:** Hypoxanthine, xanthine, uric acid, and ROS have not been measured in MKs or perivascular fluid. The functional significance of the MK fraction of PNP activity is unknown; global PNP or xanthine oxidase inhibition would affect multiple cell types, confounding MK‑specific conclusions. The inosine decrease is small, not statistically tested, and may not reflect substantial catabolic flux.  

**Revised directional chain (conditional):**
1. Hypoxia up‑regulates *Pnp* and *Nt5c2* in MKs.  
2. Enhanced PNP activity accelerates conversion of inosine to hypoxanthine (inferred from inosine drop).  
3. If hypoxanthine/xanthine/uric acid are produced and released by MKs at meaningful levels, they could feed local xanthine oxidase‑dependent ROS generation or act as DAMPs.  
4. Candidate immune‑mediated axis: Perivascular macrophage NLRP3 activation, IL‑1β release.  
5. Immune activation promotes medial remodelling.  

**Candidate downstream axes:**  
- Plausible axes (all provisional): (i) Uric acid → NLRP3 inflammasome; (ii) Hypoxanthine/xanthine oxidase → superoxide → oxidative vascular injury; (iii) Hypoxanthine acting on purinergic receptors.  
- Working model: Not assigned – no single model is sufficiently supported.  
- Specific examples kept provisional: NLRP3, IL‑1β, allopurinol‑sensitive ROS.  
- What remains unresolved: Whether MKs produce enough hypoxanthine to drive local immune activation; whether MK‑specific PNP is functionally necessary.  

**Evidence retained:**  
- User‑provided data: *Pnp* and *Nt5c2* up‑regulation in MKs; MK inosine decrease.  
- Literature: Purine catabolites as DAMPs (indirect).  

**Evidence added:** None.  

**Unsupported claims removed or downgraded:**  
- Entire hypothesis is now framed as conditional on future metabolite measurements.  
- Removed any assertion that MK‑derived purine catabolites are the primary drivers; hypothesis now reads “may contribute”.  
- Explicitly highlighted low MK enrichment.  

**Improved experimental validation (conditional):**  
- **Pre‑requisite measurement:** Quantify hypoxanthine, xanthine, uric acid in sorted PH‑MKs and conditioned medium. Only if these are elevated does the axis become actionable.  
- **If pre‑requisite met:**  
  - Perturbation: MK‑specific *Pnp* deletion (to isolate MK contribution) or xanthine oxidase inhibitor (allopurinol).  
  - Expected: Reduction in perivascular ROS/IL‑1β and partial attenuation of remodelling.  
  - Falsifying: No change in ROS/immune parameters, or allopurinol effect entirely independent of MKs.  

**Remaining weaknesses:** Intrinsic low MK specificity; no direct catabolite data; inosine change modest; likely overshadowed by non‑MK sources.  

**Recommendation:** Deprioritise until direct evidence of MK‑specific purine catabolite production is obtained. Retain as a secondary, hypothesis‑generating axis, not for immediate in vivo validation.

---

**Summary for PI:**

- **EVO‑H3** (matricellular secretome) and **EVO‑H1** (polyamine‑immune) are the two lead axes. Both share the strong AMD1/methionine anchor, but diverge at effector output. They are complementary and non‑redundant.
- **EVO‑H2‑Conditional** is a substantially weakened hypothesis that cannot be advanced without targeted purine metabolomics and MK‑specific functional data. It is kept only for completeness, with explicit flags.
- All revised hypotheses now contain a **Pre‑requisite validation** section and clearly label inferred steps.
- Unsupported claims (confirmed spermidine/hypoxanthine production, specific immune subsets, eIF5A‑target transcript status) have been removed or downgraded to provisional examples.
- The next cycle should focus on bridging the product‑level and spatial gaps—particularly LC‑MS measurement of spermidine/spermine, hypoxanthine/xanthine/uric acid, and eIF5A hypusination in sorted MKs—before launching large‑scale in vivo experiments.
